Results 11 to 20 of about 161,884 (199)

Role of inflammasome activation in tumor immunity triggered by immune checkpoint blockers [PDF]

Clinical and Experimental Immunology, 2020
Immune checkpoint blockers improve the overall survival of a limited number of patients among different cancers. Identifying pathways that influence the immunological and clinical response to treatment is critical to improve the therapeutic efficacy and ...
Mercedes Segovia, Sofía Russo, María Romina Girotti, Gabriel A. Rabinovich, Marcelo Hill   +4 more
semanticscholar   +5 more sources

Targeting the NLRP3 inflammasome abrogates cardiotoxicity of immune checkpoint blockers [PDF]

Journal for ImmunoTherapy of Cancer
Background Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of many malignant tumors. However, ICI-induced hyper-immune activation causes cardiotoxicity.
Ping Li, Zhen Qin, Yang Lu, Jiamin Gao, Zhenwei Wang, Ge Zhang, Han Yang, Yachen Hou, Dashuai Wang, Pengchong Du, Yunzhe Wang, Quanzhou Chen, Zhaowei Sun, Jinying Zhang, Junnan Tang   +14 more
doaj   +4 more sources

Oxazaphosphorines combined with immune checkpoint blockers: dose-dependent tuning between immune and cytotoxic effects [PDF]

Journal for ImmunoTherapy of Cancer, 2020
Background Oxazaphosphorines (cyclophosphamide (CPA), ifosfamide (IFO)) are major alkylating agents of polychemotherapy protocols but limiting their toxicity and increasing their efficacy could be of major interest.
Mélanie Desbois, Nathalie Chaput, Julia Delahousse, Charles Skarbek, Jean-Luc Perfettini, Angelo Paci   +5 more
doaj   +5 more sources

Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers. [PDF]

Semin Cancer Biol, 2018
Over the past few years, multiple immune checkpoint blockers (ICBs) have achieved unprecedented clinical success and have been approved by regulatory agencies for the treatment of an increasing number of malignancies. However, only a limited fraction of patients responds to ICBs employed as a standalone intervention, calling for the development of ...
Lhuillier C, Vanpouille-Box C, Galluzzi L, Formenti SC, Demaria S.   +4 more
europepmc   +5 more sources

Targeting TMEM176B Enhances Antitumor Immunity and Augments the Efficacy of Immune Checkpoint Blockers by Unleashing Inflammasome Activation. [PDF]

Cancer Cell, 2019
Although immune checkpoint blockers have yielded significant clinical benefits in patients with different malignancies, the efficacy of these therapies is still limited. Here, we show that disruption of transmembrane protein 176B (TMEM176B) contributes to CD8+ T cell-mediated tumor growth inhibition by unleashing inflammasome activation.
Segovia M, Russo S, Jeldres M, Mahmoud YD, Perez V, Duhalde M, Charnet P, Rousset M, Victoria S, Veigas F, Louvet C, Vanhove B, Floto RA, Anegon I, Cuturi MC, Girotti MR, Rabinovich GA, Hill M.   +17 more
europepmc   +9 more sources

The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1 [PDF]

OncoImmunology, 2018
Cancer immunotherapists have been searching for biomarkers predicting patient responses to PD-1/PD-L1 blockade in neoplastic cells as well as in the immune system. Now, accumulating evidence indicates that the composition of the intestinal microflora has
Lisa Derosa, Bertrand Routy, Guido Kroemer, Laurence Zitvogel   +3 more
doaj   +3 more sources

Editorial: Cellular and Molecular Mechanisms of Immune Checkpoint Blockers in Anti-leukemia/Lymphoma Immune Therapy [PDF]

Frontiers in Oncology, 2022
Mazdak Ganjalikhani-Hakemi, Ling Xu, Andrey A. Zamyatnin, Andrey A. Zamyatnin, Andrey A. Zamyatnin, Andrey A. Zamyatnin, Alexandr V. Bazhin, Alexandr V. Bazhin   +7 more
doaj   +5 more sources

Radiation unlocks the therapeutic potential of immune checkpoint blockers in lung cancer patients [PDF]

OncoImmunology, 2019
CTLA4 blockers have limited activity in patients with chemorefractory lung cancer. Recent clinical data demonstrate that radiation therapy combined with CTLA4 blockers enables disease control in a sizeable fraction of these patients, correlating with ...
Eric C. Ko, Lorenzo Galluzzi
doaj   +5 more sources

PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models. [PDF]

Oncoimmunology, 2020
PT-112 is a novel platinum-pyrophosphate conjugate under clinical development for cancer therapy. PT-112 mediates cytostatic and cytotoxic effects against a variety of human and mouse cancer cell lines in vitro.
Yamazaki T, Buqué A, Ames TD, Galluzzi L.   +3 more
europepmc   +2 more sources

Mutational Landscape and Sensitivity to Immune Checkpoint Blockers [PDF]

Clinical Cancer Research, 2016
Abstract Immunotherapy is currently transforming cancer treatment. Notably, immune checkpoint blockers (ICB) have shown unprecedented therapeutic successes in numerous tumor types, including cancers that were traditionally considered as nonimmunogenic. However, a significant proportion of patients do not respond to these therapies. Thus,
R. Chabanon, Marion Pedrero, C. Lefebvre, A. Marabelle, J. Soria, S. Postel-Vinay   +5 more
semanticscholar   +3 more sources